BOSTON, Nov. 2, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs for severe viruses oral antiviral therapy for disease, today announced two upcoming poster presentations at the 2023 Liver Session, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), to be held November 10-14, 2023 in Boston, MA .
“We are very pleased to share the supporting data for bemnifosbuvir and Ruzasvir with the scientific and clinical communities, highlighting the potential of using these two compounds together as a novel treatment for hepatitis C virus (HCV),” said Dr. Jean-Pierre Sommadossi. Atea CEO and founder of Pharmaceuticals. “We are encouraged by the highly potent, genotype-wide antiviral activity of these compounds and the favorable drug interactions and safety profiles observed to date, which support their combined use. Despite the availability of treatment options for HCV, some problem. The large, underserved population of people with hepatitis C continues to grow dramatically due to the opioid crisis, injection drug use, and hepatitis C virus reinfection.”
Details of the speech are as follows:
Poster number: 1861-A
title: Bemnifosbuvir and Ruzasvir are potent HCV DAAs with good antiviral properties against the major HCV NS5A and NS5B RAV and support combined use
Date and time: Friday, November 10, 1:00 pm – 2:00 pm
Place: Hall A
Poster number: 1879-A
title: Lack of pharmacokinetic drug interaction between benifobuvir and ruzavir in healthy subjects
Date and time: Friday, November 10, 1:00 – 2:00 pm
Place: Hall A
About Bemnifosbuvir and Ruzasvir for the treatment of hepatitis C virus (HCV)
Atea is currently conducting a Phase 2 open-label study evaluating bemnifosbuvir in combination with ruzasvir (RZR) in patients with treatment-naïve HCV infection (without cirrhosis and/or compensated cirrhosis). This study was designed to evaluate the safety and efficacy of a pan-genotypic combination of once-daily benifobuvir 550 mg and RZR 180 mg for eight weeks. Approximately 280 treatment-naïve HCV-infected patients across all genotypes are expected to be recruited, including a lead-in cohort of 60 patients.
Bemnifosbuvir is a nucleotide polymerase inhibitor that has been shown to be approximately 10 times more active than sofosbuvir (SOF) in vitro A panel of laboratory strains and clinical isolates targeting HCV genotypes 1-5. in vitro Studies have shown that bemnifosbuvir is still fully active against SOF resistance-related strains (S282T), and its potency is 58 times higher than SOF. The pharmacokinetic (PK) profile of benifobuvir supports once-daily dosing for the treatment of HCV, and benifobuvir was well tolerated in healthy and HCV-infected subjects at doses up to 550 mg, sustained The duration is 8-12 weeks.
RZR is an oral NS5A inhibitor that has demonstrated potent pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. RZR has been treated in more than 1,200 HCV-infected patients for 12 weeks at daily doses up to 180 mg and demonstrated a favorable safety profile. RZR’s PK profile supports once-daily dosing.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address unmet medical needs in patients with severe viral infections. Leveraging the company’s in-depth understanding of antiviral drug development, nucleos